Big Pharma Subdued In Its Response To Trump's Travel EO
Big pharma has been muted in its response to President Trump's executive order imposing severe travel restrictions on nationals from seven Muslim-majority countries for 90 days. Small biotech, however, has no reservations about speaking out against the so-called 'immigration ban'.
You may also be interested in...
The US, one of ICH’s original three member authorities, was spurned in favor of Canada for the pharmaceutical regulatory harmonization initiative’s next meeting in the region because of some participants’ difficulties obtaining US visas.
While PhRMA, BIO and Pfizer had no response to President Trump’s travel order, Allergan and some smaller firms voiced their objections; PhRMA to meet with Trump on Tuesday.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.